Switch theme
Sign up to access all valuation multiples
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture, and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company’s reportable segments are Unit 1 - R&D and Unit 2 : CDMO-1 (Contract Development & Manufacturing Organization); and Unit 3: Multimodal Facility and CDMO-2.
2007
525
LTM Revenue $185M
LTM EBITDA $61.7M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OneSource Specialty has a last 12-month revenue (LTM) of $185M and a last 12-month EBITDA of $61.7M.
In the most recent fiscal year, OneSource Specialty achieved revenue of $167M and an EBITDA of $43.2M.
OneSource Specialty expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OneSource Specialty valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $185M | XXX | $167M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $117M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $61.7M | XXX | $43.2M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $29.9M | XXX | $22.3M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $21.1M | XXX | -$2.1M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $71.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, OneSource Specialty's stock price is INR 1973 (or $23).
OneSource Specialty has current market cap of INR 226B (or $2.6B), and EV of INR 232B (or $2.7B).
See OneSource Specialty trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.6B | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, OneSource Specialty has market cap of $2.6B and EV of $2.7B.
OneSource Specialty's trades at 20.6x EV/Revenue multiple, and 99.2x EV/EBITDA.
Equity research analysts estimate OneSource Specialty's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OneSource Specialty has a P/E ratio of 124.0x.
See valuation multiples for OneSource Specialty and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 14.5x | XXX | 20.6x | XXX | XXX | XXX |
| EV/EBITDA | 43.5x | XXX | 99.2x | XXX | XXX | XXX |
| EV/EBIT | 89.6x | XXX | 220.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 124.0x | XXX | -202.9x | XXX | XXX | XXX |
| EV/FCF | -58.5x | XXX | -122.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOneSource Specialty's last 12 month revenue growth is 36%
OneSource Specialty's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
OneSource Specialty's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OneSource Specialty's rule of X is 122% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OneSource Specialty and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 48% | XXX | 101% | XXX | XXX | XXX |
| Rule of 40 | 56% | XXX | 56% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 122% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OneSource Specialty acquired XXX companies to date.
Last acquisition by OneSource Specialty was XXXXXXXX, XXXXX XXXXX XXXXXX . OneSource Specialty acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OneSource Specialty founded? | OneSource Specialty was founded in 2007. |
| Where is OneSource Specialty headquartered? | OneSource Specialty is headquartered in India. |
| How many employees does OneSource Specialty have? | As of today, OneSource Specialty has 525 employees. |
| Is OneSource Specialty publicy listed? | Yes, OneSource Specialty is a public company listed on NSE. |
| What is the stock symbol of OneSource Specialty? | OneSource Specialty trades under ONESOURCE ticker. |
| When did OneSource Specialty go public? | OneSource Specialty went public in 2025. |
| Who are competitors of OneSource Specialty? | Similar companies to OneSource Specialty include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of OneSource Specialty? | OneSource Specialty's current market cap is $2.6B |
| What is the current revenue of OneSource Specialty? | OneSource Specialty's last 12 months revenue is $185M. |
| What is the current revenue growth of OneSource Specialty? | OneSource Specialty revenue growth (NTM/LTM) is 36%. |
| What is the current EV/Revenue multiple of OneSource Specialty? | Current revenue multiple of OneSource Specialty is 14.5x. |
| Is OneSource Specialty profitable? | Yes, OneSource Specialty is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OneSource Specialty? | OneSource Specialty's last 12 months EBITDA is $61.7M. |
| What is OneSource Specialty's EBITDA margin? | OneSource Specialty's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of OneSource Specialty? | Current EBITDA multiple of OneSource Specialty is 43.5x. |
| What is the current FCF of OneSource Specialty? | OneSource Specialty's last 12 months FCF is -$45.8M. |
| What is OneSource Specialty's FCF margin? | OneSource Specialty's last 12 months FCF margin is -25%. |
| What is the current EV/FCF multiple of OneSource Specialty? | Current FCF multiple of OneSource Specialty is -58.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
